Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

NCT01015833 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

356

Enrollment

NIH

Sponsor class

Conditions

Advanced Adult Hepatocellular Carcinoma
Recurrent Hepatocellular Carcinoma
Stage III Hepatocellular Carcinoma AJCC v7
Stage IIIA Hepatocellular Carcinoma AJCC v7
Stage IIIB Hepatocellular Carcinoma AJCC v7
Stage IIIC Hepatocellular Carcinoma AJCC v7
Stage IV Hepatocellular Carcinoma AJCC v7
Stage IVA Hepatocellular Carcinoma AJCC v7
Stage IVB Hepatocellular Carcinoma AJCC v7
Unresectable Hepatocellular Carcinoma

Interventions

DRUG: Doxorubicin Hydrochloride
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacogenomic Study
DRUG: Sorafenib Tosylate

Sponsor

National Cancer Institute (NCI)